Physician profile
Ahmed Babiker
NPI 1407349103
$1,635.20
in general payments reported to CMS, 2019-2025
23 companies · $53.02 in 2025
The $53.02 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $126 · 2021: $566 · 2022: $412 · 2023: $162 · 2024: $90.61 · 2025: $53.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $305.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $297.97 | 2022-2024 | Proclaim, Eterna |
| Ucb, INC. | $267.59 | 2020-2024 | Briviact |
| Greenwich Biosciences, INC. | $177.51 | 2019-2021 | |
| Livanova USA, INC. | $170.71 | 2021-2022 | |
| Amgen INC. | $100.22 | 2020-2022 | |
| Emd Serono, INC. | $87.55 | 2019 | |
| Alexion Pharmaceuticals, INC. | $84.20 | 2021-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $52.96 | 2022 | |
| Abbvie INC. | $51.49 | 2024 | |
| Allergan, INC. | $44.60 | 2021 | |
| Neurelis, INC. | $36.07 | 2021 | |
| Nevro Corp. | $35.21 | 2021 | |
| Pfizer INC. | $34.50 | 2019 | |
| Sunovion Pharmaceuticals INC. | $30.38 | 2021 | |
| Portola Pharmaceuticals, LLC | $25.45 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $21.05 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.90 | 2020 | |
| Akcea Therapeutics, INC. | $19.75 | 2019 | |
| Chiesi USA, INC. | $19.18 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.42 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.39 | 2022 | |
| Genzyme Corporation | $14.05 | 2019 | |
| Natus Medical Incorporated | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Babiker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.